Zaf­gen stakes out a PhI beach­head for its next weight drug as it fights for a come­back

Last sum­mer Zaf­gen $ZFGN ex­pe­ri­enced one of the worst biotech dis­as­ters the in­dus­try wit­nessed for all of last year — the kind of night­mare that CEOs dread. Af­ter the FDA put their lead drug be­lo­ranib on clin­i­cal hold in late 2015 — link­ing it to the death of a pa­tient from a pul­monary em­bolism linked with the ther­a­py — the biotech had lit­tle choice but to kill the pro­gram in Ju­ly and slash its staff af­ter reg­u­la­tors spelled out what they would have to do to qual­i­fy for a mar­ket­ing OK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.